Patent application number | Description | Published |
20090041749 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 02-12-2009 |
20090123376 | THERAPEUTIC AGENTS WITH DECREASED TOXICITY - The present invention relates to therapeutic agents with reduced toxicity comprising a serum albumin binding peptide (SABP), a targeting agent and a cytotoxic agent. The present invention also relates to methods for reducing the toxicity of therapeutic agents and methods of treatment using the therapeutic agents with reduced toxicity. | 05-14-2009 |
20090280056 | Antibodies and immunoconjugates and uses therefor - Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP- | 11-12-2009 |
20100104588 | SERUM ALBUMIN BINDING PEPTIDES FOR TUMOR TARGETING - Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion. | 04-29-2010 |
20100121039 | METHODS AND COMPOSITIONS FOR PROLONGING ELIMINATION HALF-TIMES OF BIOACTIVE COMPOUNDS - Peptide ligands having affinity for IgG or for serum albumin are disclosed. Also disclosed are hybrid molecules comprising a peptide ligand domain and an active domain. The active domain may comprise any molecule having utility as a therapeutic or diagnostic agent. The hybrid molecules of the invention may be prepared using any of a number techniques including production in and purification from recombinant organisms transformed or transfected with an isolated nucleic acid encoding the hybrid molecule, or by chemical synthesis of the hybrid. The hybrid molecules have utility as agents to alter the elimination half-times of active domain molecules. Elimination half-time is altered by generating a hybrid molecule of the present invention wherein the peptide ligand has binding affinity for a plasma protein. In a preferred embodiment, a bioactive molecule having a short elimination half-time is incorporated as or into an active domain of the hybrid molecules of the invention, and the binding affinity of the peptide ligand domain prolongs the elimination half-time of the hybrid as compared to that of the bioactive molecule. | 05-13-2010 |
20100166741 | ALTERED BR-3 BINDING POLYPEPTIDES - The present invention relates to novel BR3 binding antibodies having altered Fc effector function and/or having a mature core carbohydrate structure in the Fc region which lacks fiicose. The present invention also relates to the use of those BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods. | 07-01-2010 |
20100280227 | POLYPEPTIDES THAT BIND BR3 AND USES THEREOF - The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods. | 11-04-2010 |
20110177103 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 07-21-2011 |
20110237779 | CDR-REPAIRED ANTIBODIES - The present application concerns restoring antigen binding during humanization of antibodies through the selection of repaired hypervariable regions rather than through framework changes. | 09-29-2011 |
20110300146 | ANTI-CMET ANTAGONISTS | 12-08-2011 |
20120082662 | ANTI-CMET ANTAGONISTS - The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies. | 04-05-2012 |
20120082663 | ANTI-CMET ANTAGONISTS - The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies. | 04-05-2012 |
20120114673 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same. | 05-10-2012 |
20120208984 | HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR - The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies. | 08-16-2012 |
20130064822 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 03-14-2013 |
20130129733 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 05-23-2013 |
20130129749 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 05-23-2013 |
20130149307 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 06-13-2013 |
20130287779 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 10-31-2013 |
20130288302 | HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR - The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies. | 10-31-2013 |
20130324704 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL | 12-05-2013 |
20140051120 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 02-20-2014 |
20140294863 | SERUM ALBUMIN BINDING PEPTIDES FOR TUMOR TARGETING - Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion. | 10-02-2014 |